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Abstract Tumor-infiltrating immune cells are associated
with tumor prognosis, although the type of immune cells
responsible for local immune escape is still unknown. This
study examined the relationship between gastric cancer
survival and the density of immune cells, including
CD8? T cells, CD20? B cells, and CD33?/p-STAT1?
cells, which represent myeloid-derived suppressor cells, to
evaluate the role of immune cells in the progression of
gastric cancer. One hundred pathologically confirmed
specimens were obtained from stage IIIa gastric cancers
between 2003 and 2006 at Sun Yat-sen University Cancer
Center, China. The density of tumor-infiltrating immune
cells in tumor tissue was examined using immunohisto-
chemical analysis. Clinicopathologic parameters and the
survival rate were analyzed in relation to the density of
immune cells. A high density of CD8? T cells and CD20?
B cells was associated with a good clinical outcome, but a
high density of CD33?/p-STAT1? cells was associated
with a poor clinical outcome. Most importantly, the density
of CD33?/p-STAT1? cells was an independent prognostic
factor and inversely related to the infiltration of CD8? T
cells. Although the infiltration of CD8? T cells and CD20?
B cells is involved in the progression of gastric cancer,
these data suggest that CD33?/p-STAT1? cells play a
central role in the regulation of the local immune response,
suggesting that CD33?/p-STAT1? cells might be thera-
peutic targets in gastric cancer.
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Introduction
Gastric cancer is one of the most aggressive diseases
worldwide, particularly in Asian countries, such as China
[1]. In addition, gastric cancer is the second leading cause
of cancer-related death each year due to the resistance and
intolerance of this cancer to cytotoxic therapy [2–4]. New
therapeutic strategies are needed to treat gastric cancer.
Recently, immunotherapy has received increased attention
because antibodies targeting immune checkpoint molecules
and therapeutic vaccines have been identified [5–8];
therefore, identifying patients who are suitable for immune
therapy is critical.
The density of tumor-infiltrating immune cells is associ-
ated with the prognosis of multiple types of tumors [9–13].
However, tumor-infiltrating immune cells consist of both
tumor-rejecting cells and tumor-promoting cells. Therefore, a
detailed analysis of tumor-infiltrating immune cells would
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lead to more effective prognostic indicators, and their
potential use as biomarkers for immunotherapy could be
determined [14, 15].
Immune cells infiltrates are different among tumor types
and from patient to patient. Tumor-infiltrating lymphocytes
(TILs) are considered to be a manifestation of the host
immune reaction to cancer cells [16]. Large numbers of T
and B lymphocytes are associated with a good clinical
outcome in many different tumor types [13, 17–26].
In addition to tumor-rejecting immune cells, immune
suppressor cells play a pivotal role in tumor progression.
Recently, several studies have demonstrated the impor-
tance of myeloid-derived suppressor cells (MDSCs) in
tumor-associated immune suppression [27, 28]. MDSCs
are recognized as a heterogeneous population of myeloid
cells that consist of immature myeloid cells (IMCs) and
myeloid cells at early stages of differentiation [27, 29, 30].
The role of the MDSCs that infiltrate into solid tumor tis-
sue is still unclear. An obstacle to assaying the role of
MDSCs in human tissue is the lack of defined markers for
MDSCs. Among the markers reported, CD33 and CD11b
are the basic markers of myeloid-derived suppressor cells.
Although they are feasible to assay in blood cells, staining
cells in tissue for multiple markers is very difficult,
especially for markers with the same subcellular localiza-
tion. To develop a set of markers that are suitable for
the detection of infiltrative MDSCs, we reviewed the
mechanisms of activation and expansion of MDSCs. The
expansion and activation of MDSCs are influenced by
several different factors, including VEGF, GM-CSG, SCF,
TGF-b, and MMP9, among others [31–39]. These factors
trigger the activation of several different signaling path-
ways in MDSCs that promote JAK-STAT signaling,
including STAT1, STAT3, and STAT6 [28, 40]. To
investigate this role, CD33 was used as a marker of
immature myeloid cells, and p-STAT1 was used as a
marker of IMCs activated by immune regulatory cytokines
[40, 41]. Therefore, CD33?/p-STAT1? cells were pro-
posed to be a subset of MDSCs in gastric cancer tissues.
This study examined the relationship between the survival
rate of gastric cancer and the density of immune cells,
including TILs and CD33?/p-STAT1? cells, which repre-
sented MDSCs, to evaluate the role of the immune
response in gastric cancer progression.
Materials and methods
Tissue specimens
Formalin-fixed, paraffin-embedded tissues from 100 gastric
cancer patients were used. Gastric cancer biopsy specimens
were collected from stage IIIa (2009 UICC staging system)
gastric cancer patients between 2003 and 2006 at the Sun
Yat-sen University Cancer Center. All of the patients
underwent radical resection, and none of the patients had
chemotherapy or radiotherapy before sample collection.
Patients received 5-FU-based adjuvant chemotherapy post-
operatively for 6 months. If recurrence or metastasis
occurred, 5-FU-based chemotherapy was given according
to the NCCN guidelines. This study was conducted in
accordance with the Declaration of Helsinki, and all
patients signed a consent form approved by the Research
Ethics Committee of the Sun Yat-sen University Cancer
Center.
Immunohistochemistry and scoring systems
Paraffin-embedded tissues were sectioned continuously at a
thickness of 4 lm and heated for 1 h at 65 C. Briefly, the
sections were deparaffinized using xylenes and rehydrated
with a graded alcohol series and distilled water. The sec-
tions were immersed in an EDTA antigen retrieval buffer
(pH 8.0), subjected to high pressure for 3 min for antigen
retrieval and allowed to cool to room temperature. After
blocking with sheep serum, the sections were incubated
overnight at 4 C with mouse monoclonal antibodies
against human CD8, CD20, and GrB (Zymed, San Diego,
CA, USA), all of which were diluted 1:400. Following
incubation with secondary antibodies, the sections were
developed using diaminobenzidine tetrahydrochloride
(DAB) and counterstained with hematoxylin.
The co-expression of CD33 and p-STAT1 was detected
with sequential immunohistochemical staining using
the EnVisonTM G/2 Doublestain System (Dako Cytoma-
tion, Glostrup, Denmark) according to the manufacturer’s
instructions. Endogenous peroxidases and alkaline phos-
phatase enzymes were blocked with the dual endogenous
enzyme-blocking reagent provided in the kit. The sections
were treated with normal goat serum for 20 min to reduce
nonspecific binding and incubated overnight at 4 C with
rabbit polyclonal anti-CD33 antibody (1:100; Protein Tech
Group, Chicago, IL, USA) and rabbit monoclonal anti-
p-STAT1 (1:400; Cell Signaling, Boston, MA, USA). For
the color reaction, diaminobenzidine (brown) and perma-
nent red (red) were must used. As a negative control, the
antibodies were replaced with phosphate-buffered saline
(PBS).
The density of immune cells within the tumor specimens
was scored as we previously reported [14]. Briefly, the
number of cells and the cell size were counted in at least
10 different fields of each section. The size of each
high-powered field (4009) was approximately 300 lm 9
300 lm, and the cells were counted in the intratumoral
compartment. The areas of highest density were chosen,
and necrotic areas were avoided. Two observers counted
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the cells at the same time in the same field using a multiple-
lens microscope. The median value was used to distinguish
the different groups of immunohistochemical variables in
the results.
Statistical analysis
All statistical analyses were performed with the SPSS 16.0
statistical software package. The median value was used
to differentiate high- and low-density groups for each
immunohistochemical variable. The correlation between
the density of immune cells and patient characteristics and
the correlation between the density of TILs and CD33?/
p-STAT1? cells were analyzed using correlation test.
Kaplan–Meier curves were used to estimate the distribution
of variables in relation to survival, which were compared
using the log-rank test. Univariate and multivariate analy-
ses were based on the Cox proportional hazards regression
model. Overall survival (OS) was defined as death from
any cause, and disease-free survival (DFS) was defined as
the time prior to relapse of the primary tumor. p \ 0.05
was considered to be statistically significant.
Results
Patient characteristics
Among the 100 patients, there were 71 men and 29 women,
and the median age was 59.5 years, with a range of
29–82 years. Fifty-five patients (55 %) were Borrmann
classification II, 38 were Borrmann classification III, and 7
cases were Borrmann classification I or IV. All of the
patients presented lymph node metastasis before treatment,
with 36 patients at the N1 stage, 34 patients at the N2 stage,
and 30 patients at the N3 stage. During follow-up, 54 died,
and 44 presented with disease progression.
CD8, CD20, GrB, and CD33?/p-STAT1? cells
in gastric cancer tissues
CD8?, CD20?, and GrB? lymphoid cells displayed strong
membrane staining (Fig. 1a–f). CD8? T cells and CD20?
B cells were primarily observed in cancer nests and along
the invasive margin. The infiltrating lymphoid cells in the
intratumoral compartment were counted.
To characterize MDSC infiltration in gastric cancer
tissue, we defined MDSCs as CD33?/p-STAT1? cells.
These CD33?/p-STAT1? double-positive cells have
been found mostly in the stroma among gastric cancer
(Fig. 1g, h), whereas they had not yet been observed in the
normal mucosa adjacent to gastric cancer and normal
mucosa far from the gastric cancer (data not shown). The
CD33 immunostaining demonstrated cytomembrane stain-
ing, and p-STAT1 demonstrated nucleus staining. Figure 1g, h
shows the CD33/p-STAT1 double-positive cells in a subset
of cells around the tumor nests.
Relationship between the density of CD33?/p-STAT1?
cells and the density of CD8? and CD20? lymphocytes
The correlation test was used to compare the density of
CD33?/p-STAT1? cells with the density of CD8? and
CD20? lymphocytes (Table 1). A higher density of CD33?/
p-STAT1? cells within tumor nests was associated with a
lower density of CD8? T cells (Spearman’s rho = -0.538,
p \ 0.001). However, CD33?/p-STAT1? cells were not
significantly associated with the density of CD20? B lym-
phocytes (Spearman’s rho = -0.036, p = 0.721).
Relationship between the density of CD8, CD20,
and CD33?/p-STAT1? cells and clinicopathologic
characteristics
The immune cells were divided into two groups based on
the median value (high density and low density). The
cutoff value for the density of CD8, CD20, and CD33?/
p-STAT1? groups was 28, 34, and 11 cells, respectively,
per high-powered field in the center of the tumor. The
density of immune cells was analyzed to identify any
association with the clinicopathologic features of gastric
cancer. As shown in Table 2, the density of CD8? T cells
and CD33?/p-STAT1? cells was significantly correlated
with patient vital status (p = 0.023, p \ 0.001) and relapse
occurrence (p = 0.005, p = 0.001); in addition, the high-
density group of CD8? T cells had a smaller tumor size
(p = 0.005). However, the density of the immune cells was
not significantly associated with gender, age, or Borrmann
classification.
Association of the density of immune cells with patient
survival
The median follow-up time was 36.5 months, with a range
of 2–88 months. The median DFS was 32.5 months, with a
range of 2–88 months. At the completion of the study, 46
patients with stage IIIa gastric cancer were alive, whereas
54 patients had died. Fifty-two deaths were cancer related,
and two deaths were unrelated to cancer. The cumulative
5-year survival rate was 32.0 % for all patients with stage
IIIa gastric cancer. We evaluated whether the density of
immune cells was associated with patient prognosis. The
disease-free survival time differed significantly between
the immune cell groups (CD8? T cells: p = 0.007; CD20?
B cells: p = 0.041; CD33?/p-STAT1? cells: p \ 0.001;
Fig. 2). Patients with a high density of lymphocytes had a
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longer DFS time than those with low density. We next
analyzed the association between the density of immune
cells and OS time (CD8? T cells: p = 0.006; CD20? B
cells: p = 0.024; CD33?/p-STAT1? cells: p \ 0.001;
Fig. 2). The cumulative 5-year survival rate was 50.9 % in
the low-density CD33?/p-STAT1? group but only 7.0 % in
the high-density CD33?/p-STAT1? group.
Univariate analysis demonstrated that age, and the
density of CD8, CD20, and CD33?/p-STAT1? cells were
significant prognostic factors for OS and DFS (Table 3).
Fig. 1 Immunohistochemical
staining for CD8, CD20, GrB,
and double immunohistochem-
ical staining for CD33 and
p-STAT1 (2009 and 4009).
a, b CD8? T lymphocytes in
gastric cancer tissue. c, d GrB?
active cytotoxic T lymphocytes
in gastric cancer tissue.
e, f CD20? B lymphocytes in
gastric cancer tissue.
g, h Gastric cancer tissue
stained for CD33? (red) and
p-STAT1? (brown)
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However, clinical prognosis was not associated with gen-
der, age, Borrmann classification, size of the tumor, or N
stage.
Multivariate Cox proportional hazard analysis
A multivariate Cox proportional hazard analysis was per-
formed for age, and the density of CD8, CD20, and
CD33?/p-STAT1? cells. Of the 100 stage IIIa gastric
cancer patients, the Cox regression model revealed that
only patients with a higher density of CD33?/p-STAT1?
cells had a significantly reduced OS (hazard ratio [HR]:
4.674; 95 % CI: 2.525–8.625) and DFS (HR: 4.670; 95 %
CI: 2.537–8.596) compared to the low CD33?/p-STAT1?
group. However, CD8 and CD20 were not associated with
OS or DFS (Table 4).
Discussion
To enhance our understanding of the contribution of the
local immune response to the progression of gastric cancer,
this study characterized CD8? T lymphocytes, CD20? B
lymphocytes, and CD33?/p-STAT1? cells in the intratu-
moral region. The results showed that the density of CD8?
T cells, CD20? B cells, and CD33?/p-STAT1? cells in
tumors was a useful criterion for the prediction of survival
in advanced gastric cancer patients. Most importantly, Cox
multivariate analysis demonstrated that the density of
CD33?/p-STAT1? cells within the cancer tissue was an
independent prognostic factor. These data indicated that
CD33?/p-STAT1? cells play an important role in the
progression of gastric cancer.
Several recent studies have analyzed the important role
of tumor-infiltrating cytotoxic CD8? T and B lymphocytes
in the antitumor immune response [42–49]. The effects of
CD8? T cells in cancer cell nests might be related to the
effector function of killer T cells, and the role of B lym-
phocytes as part of the adaptive humoral immune response
has been associated with improved survival in several types
of cancer [25, 26, 50].
Although some studies have indicated that immune
surveillance and immune escape exist in gastric cancer
Table 1 Relationship between CD33?/p-STAT1? cells and the
density of TILs
CD33?/p-STAT1? cells
Spearman’s rho p value
Density of CD8? T cells -0.538 \0.001
Density of CD20? B cells -0.036 0.721
Table 2 Correlation between clinicopathologic features and immune cell density
Characteristics CD8? T lymphocytes CD20? B lymphocytes CD33?/p-STAT1? cells
High density Low density p High density Low density p High density Low density p
(n = 38) (n = 62) (n = 43) (n = 57) (n = 43) (n = 57)
Gender
Male 31 40 0.068 32 39 0.513 28 43 0.260
Female 7 22 11 18 15 14
Age (year)
\60 11 17 0.869 10 18 0.359 14 14 0.378
C60 27 45 33 39 29 43
Borrmann classification
I 2 2 0.554 2 2 0.884 1 3 0.950
II 23 32 22 33 24 31
III 13 25 18 20 17 21
IV 0 3 1 2 1 2
Tumor size (cm3)
\20 25 23 0.005 20 28 0.796 22 26 0.582
C20 13 39 23 29 21 31
Vital status
Alive 23 23 0.023 19 27 0.752 9 37 \0.001
Dead 15 39 24 30 34 20
Relapse
Yes 10 34 0.005 18 26 0.708 27 17 0.001
No 28 28 25 31 16 40
Med Oncol (2013) 30:442 Page 5 of 9
123
[51–53], the type of immune cells responsible for local
immune escape is still unknown. Experimental data indi-
cated that MDSCs suppress the immune response, in con-
trast to CD8? T cells and CD20? B cells. The main
obstacle is the markers for MDSCs in the human tissue. As
mentioned above, besides the basic markers of human
MDSCs, the signaling pathways associate with the MDSCs
expansion and activation are also very important. STAT1 is
one of the pathways in MDSCs activation; Gabrilovich
demonstrated that STAT1 activation in tumor-associated
macrophages is responsible for the upregulation of induc-
ible nitric oxide synthase (iNOS) and arginase 1 activity in
these cells, which results in T-cell suppression [41].
STAT1-deficient MDSCs are unable to inhibit T-cell acti-
vation due to their inability to upregulate iNOS and argi-
nase 1 activity [54, 55]. Therefore, CD33 staining on the
cell membrane was used as a marker of myeloid cells in
this study, and p-STAT1 nuclear staining was used to
Fig. 2 Kaplan–Meier analysis
of disease-free survival and
overall survival for each
immune cell group. A high
density of CD8? T lymphocytes
and CD20? B lymphocytes was
associated with a longer overall
survival and longer disease-free
survival than a low density, but
the inverse result was observed
for CD33?/p-STAT1? cell
density
Table 3 Univariate analysis of factors associated with OS and DFS
Variables OS (n = 100) DFS (n = 100)
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represent a transcription factor activated by pro-inflam-
matory cytokines. For this reason, CD33?/p-STAT1? cells
are defined as a specific type of MDSC in gastric cancer
tissues, although further functional analysis is required.
Using this set of MDSC markers, it was possible to
examine the infiltration of MDSCs into cancer tissues.
To confirm the role of CD33?/p-STAT1? cells, which
represented MDSCs in gastric cancer tissue, this study
detected the density of CD8? T cells, CD20? B cells, and
CD33?/p-STAT1? immune cells infiltrating tumor tissue.
A higher density of CD33?/p-STAT1? cells was inversely
related to infiltrating CD8? T lymphocytes but not B cells,
supporting that CD33?/p-STAT1? cell might be a subset
of MDSCs in gastric tumor tissue. Although Kaplan–Meier
analysis and log-rank tests revealed that the all of the
immune cells were significantly associated with OS and
DFS duration, Cox multivariate analysis demonstrated that
only the density of CD33?/p-STAT1? cells within the
cancer tissue was a prognostic factor for OS and DFS,
independently, indicating that CD33?/p-STAT1? cells
play a key role in the regulation of the local immune
response.
Overall, this study demonstrated that the density of
CD33?/p-STAT1? cells is an independent prognostic
factor for patients with stage IIIa gastric cancer, indicating
that CD33?/p-STAT1? cells play a central role in the local
immune response in gastric cancer. Therefore, CD33?/p-
STAT1? cells might be a useful therapeutic target.
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